Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications.: Fluorinated lipid nanocapsules as oxygen sensor

Elodie Moysan 1 Guillaume Bastiat 2, * Jean-Pierre Benoit 1
* Auteur correspondant
2 INSERM U1066
MINT - Micro et nanomédecines biomimétiques
Abstract : Gemcitabine, an anticancer agent which acts against a wide range of solid tumors, is known to be rapidly deaminated in blood to the inactive metabolite 2',2'-difluorodeoxyuridine and to be rapidly excreted by the urine. Moreover, many cancers develop resistance against this drug, such as loss of transporters and kinases responsible for the first phosphorylation step. To increase its therapeutic levels, gemcitabine is administered at high doses (1000 mg/m(2)) causing side effects (neutropenia, nausea, and so forth). To improve its metabolic stability and cytotoxic activity and to limit the phenomena of resistance many alternatives have emerged, such as the synthesis of prodrugs. Modifying an anticancer agent is not new; paclitaxel or ara-C has been subjected to such changes. This review summarizes the various chemical modifications that can be found in the 4-(N)- and 5'-positions of gemcitabine. They can provide (i) a protection against deamination, (ii) a better storage and (iii) a prolonged release in the cell, (iv) a possible use in the case of deoxycytidine kinase deficiency, and (v) transporter deficiency. These new gemcitabine-based sysems have the potential to improve the clinical outcome of a chemotherapy strategy.
Type de document :
Article dans une revue
Molecular Pharmaceutics, American Chemical Society, 2013, 10 (2), pp.430-44. 〈10.1021/mp300370t〉
Liste complète des métadonnées

Littérature citée [121 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00787112
Contributeur : Laurent Lemaire <>
Soumis le : mardi 1 octobre 2013 - 07:00:13
Dernière modification le : mardi 19 juin 2018 - 15:18:01
Document(s) archivé(s) le : samedi 1 avril 2017 - 22:01:23

Fichier

MOYSAN_2013_molecular_pharmace...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Elodie Moysan, Guillaume Bastiat, Jean-Pierre Benoit. Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications.: Fluorinated lipid nanocapsules as oxygen sensor. Molecular Pharmaceutics, American Chemical Society, 2013, 10 (2), pp.430-44. 〈10.1021/mp300370t〉. 〈inserm-00787112〉

Partager

Métriques

Consultations de la notice

773

Téléchargements de fichiers

1507